Prognostic Impact of Immune-Related Adverse Events as First-Line Therapy for Metastatic Renal Cell Carcinoma Treated With Nivolumab Plus Ipilimumab: A Multicenter Retrospective Study

Takuhisa Nukaya(Fujita Health University), Ryoichi Shiroki(Fujita Health University), Yosuke Hirasawa(Cedars-Sinai Medical Center), Takuya Tsujino(Osaka University of Pharmaceutical Sciences), Atsuhiko Yoshizawa(Fujita Health University Hospital), Fumihiko Urabe(Jikei University School of Medicine), Kosuke Iwatani(Jikei University School of Medicine), Shogo Yamazaki(Osaka University of Pharmaceutical Sciences), Yusuke Yano(Osaka University of Pharmaceutical Sciences), Wataru Fukuokaya(Jikei University School of Medicine), Keita Nakamori(Osaka University of Pharmaceutical Sciences), Haruhito Azuma(Osaka University of Pharmaceutical Sciences), Jun Miki(Jikei University School of Medicine), Keiichiro Mori(Jikei University School of Medicine), Kazuki Nishimura(Osaka University of Pharmaceutical Sciences), Takafumi Yanagisawa(Jikei University School of Medicine), Takahiro Adachi(Tokyo Medical University), Shunsuke Tsuduki(Jikei University School of Medicine), Shutaro Yamamoto, Masanobu Saruta(Fujita Health University), Yoshio Ohno(Tokyo Medical University), Teruo Inamoto(Hamamatsu University), Takeshi Hashimoto(Tokyo Medical University), Kazumasa Komura(Kawasaki Medical School), Satoshi Tokushige(Osaka University of Pharmaceutical Sciences), Takahiro Kimura(Jikei University School of Medicine), Takaya Ohno(Osaka University of Pharmaceutical Sciences), Taizo Uchimoto(Osaka University of Pharmaceutical Sciences), Kiyoshi Takahara(Osaka Medical and Pharmaceutical University)
Clinical Genitourinary Cancer
October 1, 2023
Cited by 8


Related Papers